Tracking Cosmos 482: When will the Soviet-era spacecraft return to Earth?
A 50-plus-year-old Soviet-era spacecraft is expected to return to Earth this weekend.
Cosmos 482 was launched to space by the Soviet Union in March 1972, with the intent of landing on Venus to conduct scientific measurements. However, an apparent engine malfunction kept the spacecraft from landing properly and since, it has remained abandoned in Earth's low-orbit. Until now.
Just a few weeks after its 53rd launch anniversary, Cosmos 482 is expected to descend back to Earth's atmosphere between Friday, May 9 and Saturday, May 10, according to NASA. When and where the spacecraft will land though, remains unknown to officials.
Here's what to know about Cosmos 482 and its return to Earth.
Various space entities give a variety of estimates of when the spacecraft could make its return, but the latest projections center on the early morning hours of Saturday, May 10. Here are the latest projections of when the spacecraft could re-enter Earth, as of midday Friday, May 9:
NASA expects Cosmos 482 to return to Earth roughly around 3:30 a.m. ET on Saturday, May 10.
The European Space Agency predicts the spacecraft to return around 2:26 a.m. ET on Saturday, May 10.
And The Aerospace Corporation, a federally-funded research and development center, predicts Cosmos 482 to re-enter Earth's orbit around 1:54 a.m. ET on Saturday, May 10.
Officials are unsure of where exactly Cosmos 482 will land.
As of Friday, both NASA and the European Space Agency predict the spacecraft to land somewhere between 52 N and 52 S latitude, which encompasses the majority of the northern and southern hemispheres.
Reentries can be possible to see from the ground, but Cosmos 482's reentry visibility will be dependent on where it lands. If the spacecraft lands in the ocean or an unpopulated area, it won't be easy to spot, The Aerospace Corporation stated. If the spacecraft lands in a population area, it will need to be dark to see it best.
It is unlikely that Cosmos 482 is a danger risk to humans. The spacecraft is smaller and lighter than other objects The Aerospace Corporation typically raises awareness about, the nonprofit reported.
If Cosmos 482 remains fully intact as it reenters Earth's atmosphere, The Aerospace Corporation projects a risk of 0.40 in 10,000.
Though it is unlikely Cosmos 482 would land in anyone's yard, The Aerospace Corporation reminds folks that if this were to happen, do not touch the spacecraft because it could be potentially hazardous. Again though, it is much more likely that Cosmos 482 will land in the ocean or an unpopulated area.
Cosmos 482, also known as Kosmos 482, was one in a pair of identical Venus atmospheric lander probes that the Soviet Union launched in 1972. The other spacecraft, Venera 8, successfully arrived to Venus to make scientific measurements of the planet's soil before ceasing operation.
Cosmos 482 launched four days after Venera 8 and it is believed that a malfunction resulted in an engine burn, which did not achieve the needed velocity to reach Venus' atmosphere, according to NASA. The spacecraft separated into four pieces, two of which remained in Earth's low orbit and decayed within 48 hours, and the other two pieces went into a higher orbit.
Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@usatoday.com.
This article originally appeared on USA TODAY: Tracking Cosmos 482's reentry: What time will it return to Earth?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C. Wainwright, raised the price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) from $53 to $56 and kept the stock's buy rating. A team of scientists in white lab coats reviewing lab results in a research facility. Positive momentum for the company is proven by the fast uptake of the Attruby product, which is the driving force behind this bullish forecast. For adult patients with ATTR-CM, Attruby is the only nearly full (≥90%) stabilizer of Transthyretin (TTR) that has been approved in the United States to lower cardiovascular mortality and hospitalizations linked to cardiovascular disease. In general, Attruby was highly received. Abdominal pain and diarrhea were the most frequent, moderate side effects that went away without stopping the medication. BridgeBio Pharma, Inc. (NASDAQ:BBIO) provides a wide range of initiatives to facilitate patients' access to our medications. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a novel biopharmaceutical business that was established to find, develop, test, and distribute revolutionary medications to treat people with hereditary disorders. The development programs in its pipeline span from early science to advanced clinical trials. BBIO is among the stocks with the biggest upside. While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
an hour ago
- Yahoo
Ancient Roman Villa, Largest of Its Kind, Unearthed in France
Archaeologists in France have unearthed one of the largest Roman-era villas ever found in the country, the Institut National de Recherches Archéologiques Préventives (French National Institute for Preventive Archaeological Research—INRAP) reported. The villa was discovered in Burgundy and is believed to have once belonged to an aristocratic Roman who owned a great deal of land in the area. The site has been recognized as an archaeological site since the 19th century, but proper excavations didn't begin until 1966 when one structure, spanning 700 square meters, was unearthed. With the latest discovery, which spans 4,000 m², scientists now believe that the first structure was just one piece of a much larger compound. The most recent excavation revealed a substantial residential area located near a spacious garden measuring about 900 m², which led to a quadrangular pool on one side and a fountain on the other, both of which were common fixtures of Roman-era garden design. Fencing the garden were colonnaded galleries which led to an assortment of technical rooms, reception halls, and staff quarters, including what was likely a kitchen. The complex's eastern wing was found to contain a large bathing complex. Researchers believe that the layout suggests the complex was constructed in two or three different phases. Though only part of it has been recovered, it is already one of the most expansive Roman encampments ever discovered in the region. The materials and relics found at the site will undergo further analysis to determine details about the daily lives of the complex's Roman Villa, Largest of Its Kind, Unearthed in France first appeared on Men's Journal on Jun 11, 2025
Yahoo
an hour ago
- Yahoo
Establishment Labs Hosting Investor Day on June 12
NEW YORK, June 11, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data